Sangamo Therapeutics Inc. Watch

from 10-Q 4 pages Material contract

from 10-Q 70 pages License Agreement

from 8-K 38 pages 1. Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan Adopted by the Compensation Committee of the Board: April 23, 2018 Approved by the Stockholders: June 11, 2018 Amended and Restated by the Compensation Committee of the Board: March 20, 2020 Approved by the Stockholders: May 18, 2020 Amended and Restated by the Board: February 23, 2022 Amended and Restated by the Compensation Committee of the Board: March 25, 2022 Approved by the Stockholders: May 24, 2022 Amended and Restated by the Board: February 21, 2023 Amended and Restated by the Compensation Committee of the Board: March 23, 2023 Approved by the Stockholders: June 1, 2023 Amended and Restated by the Board: March 28, 2024 Amended and Restated by the Compensation Committee of the Board: March 28, 2024 Approved by the Stockholders: June 4, 2024

from 10-Q 7 pages Material contract

from 8-K 40 pages Sangamo Therapeutics, Inc. 24,761,905 Shares of Common Stock Par Value $0.01 Per Share Pre-Funded Warrants to Purchase Up to 3,809,523 Shares of Common Stock Warrants to Purchase 28,571,428 Shares of Common Stock Placement Agent Agreement

from 8-K 41 pages Securities Purchase Agreement

from 10-K 3 pages Material contract

from 10-K 3 pages Material contract

from 10-K 8 pages October 16, 2023 Version 1.0 Incentive Compensation Recoupment Policy

from 10-Q 24 pages Material contract

from 8-K 37 pages 286911297 V2 1. Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan Adopted by the Compensation Committee of the Board: April 23, 2018 Approved by the Stockholders: June 11, 2018 Amended and Restated by the Compensation Committee of the Board: March 20, 2020 Approved by the Stockholders: May 18, 2020 Amended and Restated by the Board: February 23, 2022 Amended and Restated by the Compensation Committee of the Board: March 25, 2022 Approved by the Stockholders: May 24, 2022 Amended and Restated by the Board: February 21, 2023 Amended and Restated by the Compensation Committee of the Board: March 23, 2023 Approved by the Stockholders: June 1, 2023

from 10-K 26 pages Material contract

from 10-Q 6 pages Executive Employment Agreement

from 8-K 32 pages 1. General

from 10-K 29 pages Material contract

from 10-K 6 pages Executive Employment Agreement

from 10-Q 7 pages Executive Employment Agreement

from 10-Q 7 pages Executive Employment Agreement

from 10-Q 21 pages Executive Employment Agreement

from 10-Q 15 pages Material contract